Jiachen Xu

8PUBLICATIONS
42CO-AUTHORS
Predictive and prognostic markersInnate immunityMolecular targetsEpigenetics (incl. genome methylation and epigenomics)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 24, 2025
Author Correction: Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy.

Jiefei Han, Yiting Dong, Xiuli Zhu

|Feb 08, 2024
Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy.

Jiefei Han, Yiting Dong, Xiuli Zhu

|Jan 17, 2024
Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1/PD-L1 inhibitors.

Xiang Li, Yangzhong Zhou, Bing Xu

|May 24, 2023
Abnormal activation of NF-κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid-derived suppressor cells to shape the immunosuppressive tumor immune microenvironment.

Chao Wang, Kailun Fei, Lihui Liu

|Apr 07, 2023
Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors.

Boyang Sun, Tian Qiu, Xiaoling Zeng

|May 25, 2022
TIGIT/CD47 dual high expression predicts prognosis and is associated with immunotherapy response in lung squamous cell carcinoma.

Yue Peng, Bin Qiu, Fengwei Tan

Pageof 2

Frequent Collaborators

6 joint publications

Jie Wang

4 joint publications

Jianchun Duan

4 joint publications

Zhijie Wang

3 joint publications

Jiefei Han